SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001628280-24-021971
Filing Date
2024-05-09
Accepted
2024-05-09 08:00:42
Documents
15
Period of Report
2024-05-09
Items
Item 2.02: Results of Operations and Financial Condition
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K mnlo-20240509.htm   iXBRL 8-K 25644
2 EX-99.1 vyne-20240509q12024exx991.htm EX-99.1 91701
6 GRAPHIC imagea.jpg GRAPHIC 16124
  Complete submission text file 0001628280-24-021971.txt   274392

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT mnlo-20240509.xsd EX-101.SCH 2028
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT mnlo-20240509_lab.xml EX-101.LAB 21885
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT mnlo-20240509_pre.xml EX-101.PRE 12621
18 EXTRACTED XBRL INSTANCE DOCUMENT mnlo-20240509_htm.xml XML 2720
Mailing Address 685 ROUTE 202/206 N., SUITE 301 BRIDGEWATER NJ 08807
Business Address 685 ROUTE 202/206 N., SUITE 301 BRIDGEWATER NJ 08807 800-775-7936
VYNE Therapeutics Inc. (Filer) CIK: 0001566044 (see all company filings)

IRS No.: 453757789 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-38356 | Film No.: 24928677
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)